# Alexandra S Troyan

List of Publications by Year
in descending order



| 10 | 177 | 1307594 7 | 1474206 9 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 10 | 10 | 10 | 327 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective. Medical Hypotheses, 2020, 138, 109610. | 1.5 | 7 |
| 2 | The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy. Frontiers in Psychiatry, 2020, 11, 800. | 2.6 | 11 |
| 3 | Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study. BMC Psychiatry, 2020, 20, 208. | 2.6 | 10 |
| 4 | Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders, 2019, 250, 114-122. | 4.1 | 27 |
| 5 | Specific Cognitiveâ€“Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Caseâ€“Control Study. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 256-264. | 2.3 | 1 |
| 6 | Poststroke Depression Biomarkers: A Narrative Review. Frontiers in Neurology, 2018, 9, 577. | 2.4 | 61 |
| 7 | P300 parameters as markers for early stages of subcortical vascular neurocognitive disorder and treatment efficacy. European Neuropsychopharmacology, 2017, 27, S1037-S1038. | 0.7 | 0 |
| 8 | Neuropsychiatric Symptoms in Patients with the Main Etiological Types of Mild Neurocognitive Disorders: A Hospital-Based Caseâ€“Control Study. Frontiers in Psychiatry, 2017, 8, 75. | 2.6 | 6 |
| 9 | Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry, 2017, 16, 38. | 2.7 | 32 |
| 10 | Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Disease Markers, 2016, 2016, 1-7. | 1.3 | 22 |